168 related articles for article (PubMed ID: 38321902)
1. Therapeutic Potential of Iron Chelators in Viral Diseases: A Systematic Review.
Lori MS; Khandani AK; Dehghannoudeh G; Ohadi M; Ansari M
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38321902
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological mechanism and therapeutic efficacy of Icariside II in the treatment of acute ischemic stroke: a systematic review and network pharmacological analysis.
Wang X; Li J; Liu L; Kan JM; Niu P; Yu ZQ; Ma C; Dong F; Han MX; Li J; Zhao DX
BMC Complement Med Ther; 2022 Sep; 22(1):253. PubMed ID: 36180911
[TBL] [Abstract][Full Text] [Related]
4. Synthetic and natural iron chelators: therapeutic potential and clinical use.
Hatcher HC; Singh RN; Torti FM; Torti SV
Future Med Chem; 2009 Dec; 1(9):1643-70. PubMed ID: 21425984
[TBL] [Abstract][Full Text] [Related]
5. New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.
Kontoghiorghes GJ; Kolnagou A; Demetriou T; Neocleous M; Kontoghiorghe CN
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074010
[TBL] [Abstract][Full Text] [Related]
6. The role of iron chelation in cancer therapy.
Buss JL; Torti FM; Torti SV
Curr Med Chem; 2003 Jun; 10(12):1021-34. PubMed ID: 12678674
[TBL] [Abstract][Full Text] [Related]
7. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
[TBL] [Abstract][Full Text] [Related]
9. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
Dalamaga M; Karampela I; Mantzoros CS
Metabolism; 2020 Jul; 108():154260. PubMed ID: 32418885
[TBL] [Abstract][Full Text] [Related]
10. [Susceptibility of enterococci to natural and synthetic iron chelators].
Lisiecki P; Mikucki J
Med Dosw Mikrobiol; 2002; 54(4):317-24. PubMed ID: 12650054
[TBL] [Abstract][Full Text] [Related]
11. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis.
Oba Y; Anwer S; Patel T; Maduke T; Dias S
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD013797. PubMed ID: 37602534
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroids in children with persistent asthma: effects on growth.
Zhang L; Prietsch SO; Ducharme FM
Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV effect of iron chelators: different mechanisms involved.
van Asbeck BS; Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ
J Clin Virol; 2001 Feb; 20(3):141-7. PubMed ID: 11166663
[TBL] [Abstract][Full Text] [Related]
15. Synthetic and natural products as iron chelators.
Sharpe PC; Richardson DR; Kalinowski DS; Bernhardt PV
Curr Top Med Chem; 2011; 11(5):591-607. PubMed ID: 21189130
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium in asthma: a systematic review.
Befekadu E; Onofrei C; Colice GL
J Asthma Allergy; 2014; 7():11-21. PubMed ID: 24600237
[TBL] [Abstract][Full Text] [Related]
17. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Kontoghiorghes GJ; Kolnagou A
Curr Med Chem; 2005; 12(23):2695-709. PubMed ID: 16305466
[TBL] [Abstract][Full Text] [Related]
18. Management of Iron Overload in Resource Poor Nations: A Systematic Review of Phlebotomy and Natural Chelators.
Orisakwe OE; Amadi CN; Frazzoli C
J Toxicol; 2020; 2020():4084538. PubMed ID: 32399029
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassemia patients: a systematic review and meta-analysis for effect on iron overload.
Darvishi-Khezri H; Naderisorki M; Zahedi M; Mortazavi P; Tajik F; Nasirzadeh A; Karami H
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1445-1453. PubMed ID: 34486906
[No Abstract] [Full Text] [Related]
20. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
